Bristol's Opdivo Enjoys IO First-Mover Advantage In Small Cell Lung Cancer

In addition to Opdivo, three other PD-1/L1 inhibitors are in late-stage development for a high-unmet need disease, including Roche's Tecentriq, which will be filed as soon as possible.